Cathelyne Elisabeth Hollibaugh, MA, CCC-SLP | |
12155 W 68th Pl, Arvada, CO 80004-2318 | |
(706) 347-0691 | |
Not Available |
Full Name | Cathelyne Elisabeth Hollibaugh |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 12155 W 68th Pl, Arvada, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245558402 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Cathelyne Elisabeth Hollibaugh, MA, CCC-SLP 12155 W 68th Pl, Arvada, CO 80004-2318 Ph: (706) 347-0691 | Cathelyne Elisabeth Hollibaugh, MA, CCC-SLP 12155 W 68th Pl, Arvada, CO 80004-2318 Ph: (706) 347-0691 |
News Archive
Consuming carbohydrates with high glycemic index—an indicator of how quickly a food affects blood glucose levels—appears to be associated with the risk of coronary heart disease in women but not men, according to a report in the April 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.
Rick Santorum snapped his four-state losing streak Tuesday with wins in three GOP presidential caucuses. Meanwhile, the GOP candidates are hitting front-runner Mitt Romney on the similarity of a rule he presided over in Massachusetts that required even Catholic hospitals to provide the morning-after pill - comparing it to a recent Obama administration controversy on contraception.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Wall Street Journal reports that insurers are bringing their insurance plans in compliance with new rules and laws that make mental health and substance abuse insurance coverage available to millions of Americans.
› Verified 7 days ago
Kay, Lynn Swanson, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7015 Nile Ct, Arvada, CO 80007 Phone: 303-503-3742 | |
Serena Laughren, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 9713 W 57th Pl, Arvada, CO 80002 Phone: 720-722-0411 | |
Caitlin Page, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6616 Reed Ct, Arvada, CO 80003 Phone: 720-434-7777 | |
Mrs. Lisa Moore, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9353 Iron Mountain Way, Arvada, CO 80007 Phone: 937-313-5347 | |
Clg Solutions Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9090 Flora St, Arvada, CO 80005 Phone: 720-435-0350 | |
Speech Garden Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9713 W 57th Pl, Arvada, CO 80002 Phone: 720-722-0411 | |
Carly Melissa Murray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8448 Otis Dr, Arvada, CO 80003 Phone: 303-570-3181 |